VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.

Watson Pharmaceuticals, Inc. was founded in 1983 and is based in Corona, California. Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacture, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products. Watson operates and manages its business as three operating segments: Generic, Brand and Distribution. As of December 31, 2008, the Company marketed approximately 150 generic pharmaceutical product families and 27 brand pharmaceutical product families through its generic and brand divisions, respectively, and distributed approximately 8,000 stock-keeping units (SKUs) through its distribution division. The Company’s operations are based predominantly in the United States and India, with its key commercial market being the United States. In December 2009, the Company completed the acquisition of Arrow Group. In January 2010, the Company completed the acquisition of Eden Biopharm Group Limited.

Cyprotex PLC is a holding company, which is engaged in the provision of in vitro and in silico ADMET/PK (Absorption, Distribution, Metabolism, Excretion, Toxicity/Pharmacokinetic) information to the pharmaceutical industry. The Company developed a suite of services and technologies known as Cloe (Cyprotex Lead Optimisation Engine). It combines in vitro screening with pharmacokinetic prediction system to offer an integrated suite of ADME services to the pharmaceutical and biotechnology companies worldwide. During the year ended December 31, 2008, the Company introduced a new Cloe product line, Cloe Select, which focuses on studies performed of drug discovery or preclinical development stage. Its subsidiaries include Cyprotex Discovery Ltd, Cyprotex Research Ltd and Cyprotex North America, Inc.

Hi-Tech Pharmacal Co., Inc. was founded in 1982 and is based in Amityville, New York. Hi-Tech Pharmacal Co., Inc. (Hi-Tech) is a specialty manufacturer and marketer of prescription, over-the-counter (OTC) and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and OTC brands. It produce a range of products for various disease states, including asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care, neurological disorders, glaucoma and other conditions. The Company’s generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments, as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. On February 27, 2009, the Company purchased substantially all of the assets of E. Claiborne Robins Company, Inc. doing business as, ECR Pharmaceuticals (ECR Pharmaceuticals or ECR).

The Wellcome Trust Sanger Institute (Sanger Institute) is a leading research center dedicated to analyzing and understanding genomics. Best known for its work on the Human Genome Project (the institute is responsible for sequencing one-third of the human genome), the Sanger Institute is applying genomics to the study of organisms that cause diseases such as malaria, typhoid, and tuberculosis. The institute was founded in 1993 by the Wellcome Trust and the Medical Research Council, and has been funded by a $430 million grant from the Wellcome Trust since 2001.

Henderson Morley takes aim at those pesky microscopic parasites we know as viruses. The company researches and develops vaccines and treatments for viral infections by preventing them from replicating once they invade their host cells. One of its lead product candidates is a vaccine for genital herpes that could be used as a preventative or a therapeutic measure. Other candidates target human cytomegalovirus and human papillomavirus. Instead of taking its candidates through all phases of development, Henderson Morley instead looks to out-license its candidates. Chairman Andrew Knight owns 34% of the company.

Since its establishment in 1982, Orgenics' objective has been to develop accurate and safe diagnostic products for serious and life-threatening conditions and diseases. Orgenics contributes to the increased awareness and early detection of HIV, infectious diseases, pregnancy and fertility, respiratory diseases, cancer and cardiology through clinical and point-of-care diagnostics. Orgenics delivers products and solutions to partners and customers in over 150 countries around the globe.Orgenics unique and patented ImmunoComb® technology is quick and easy to use, providing high sensitivity and specificity. Instrument free Orgenics' ImmunoComb® kits are ideal for decentralized clinical laboratories, field hospitals and remote rural areas. Orgenics' ImmunoLISA™ system is based on classic ELISA assay principle and is suitable for any laboratory setting.

Huntingdon Life Sciences Limited, a subsidiary of Life Sciences Research, is a leading contract research organization (CRO) that tests the safety of agrochemicals, foods, flavorings, industrial chemicals, pharmaceuticals and veterinary products. Huntingdon Life Sciences also provides drug development services for biotechnology and pharmaceutical companies, including Phase I-III testing, genetic toxicology assays, and microbiological activities.

Spherotech, Inc. company was founded in 1992. pherotech is very particular about its business. Spherotech company manufactures microparticles for the drug and medical device industries. Its product offerings include ferromagnetic, fluorescent, latex, paramagnetic, and various colored microparticles. Spherotech's products are used in applications such as fluorescence and enzyme immunoassay.

TopoTarget A/S company develops and markets anti-cancer drugs, as well as therapies for cancer-related conditions. Its portfolio includes preclinical candidates, drugs in clinical development, and marketed products. Its Savene therapy is sold in Europe and is a detoxifying drug which limits tissue damage after accidental exposure to certain chemotherapy agents; the drug is also marketed as Totect in the US. Founded in 2000, TopoTarget works with academic and commercial development partners in the US and Europe. Its biopharmaceutical candidates aim to fight cancers such as lymphoma, melanoma, and ovarian, breast, and neck cancers.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.